Brief: AUM Biosciences Receives FDA Orphan Drug Designation For Aum302 For The Treatment Of Neuroblastoma

Mountain Crest Acquisition V

30/11/2022 14:39

Nov 30 (Reuters) - Mountain Crest Acquisition Corp V
 MCAGU.O :
    * AUM BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
AUM302
FOR THE TREATMENT OF NEUROBLASTOMA
    * AUM BIOSCIENCES RECEIVES FDA ORPHAN DRUG DESIGNATION FOR
AUM302
FOR THE TREATMENT OF NEUROBLASTOMA

Source text for Eikon:  ID:nGNXHGFdK 
Further company coverage:  MCAGU.O 
 ((Reuters.Briefs@thomsonreuters.com;;))